Allegiance Equity Corporation
(Public, CVE:ANQ) Watch this stockFind more results for
ANQ
Key stats and ratios
| Q2 (Jun '09) | 2009 | |
| Net profit margin | -150.00% | -86.24% |
| Operating margin | -150.00% | -86.24% |
| EBITD margin | - | -85.91% |
| Return on average assets | -36.93% | -115.25% |
| Return on average equity | -85.95% | -200.78% |
Address
79 Old Forest Hill Road
Toronto, ON M5P 2R6
Canada
+1-416-4896660 (Phone)
+1-416-4822558 (Fax)
Toronto, ON M5P 2R6
Canada
+1-416-4896660 (Phone)
+1-416-4822558 (Fax)
Website links
Company website:
http://www.allegianceequity.com/
http://www.allegianceequity.com/
Allegiance Equity Corporation discussions
View all discussions »Description
Allegiance Equity Corporation is engaged in providing financial and business capability to emerging corporations primarily in the pharmaceutical, medical and biotechnology industries. Its subsidiaries include Prime Pharmaceutical Corporation (Prime) and Primapharm Funding Corporation (Primapharm). The Company has an interest in Masonburg Properties, Posters Plus and First Eastern. The Company has a 14.68% interest in Innovative Life Sciences Corporation. The Company through its subsidiary, Prime, has a 10% interest in Apollo Pharmaceutical Inc.
Officers and directors
| David S. Solomon | President, Director | |
| Marilyn H. Bloovol | Secretary, Director | |
| Melvin Goldberg | Director | |
| Donald Stott | Director | |
| William Vukson | Director |